Otros idiomas Vaxcyte, Inc.

Acciones

PCVX

US92243G1085

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 29/04/2024			Varia. Cinco días.	Varia. 1 de enero.
61,03 ^USD	+0,51 %		-0,93 %	-2,82 %

25/04	Un insider de Vaxcyte vendió acciones por valor de 928.845 dólares, según un reciente registro de la SEC	MT
22/04	Un iniciado de Vaxcyte vendió acciones por valor de 490.199 dólares, según un reciente registro de la SEC	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	25/04
Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	22/04
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Certain Pre-Funded Warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing	21/03
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants	04/03
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	04/03
Vaxcyte Q4 Loss Widens	27/02
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	27/02
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024	15/02
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	03/02
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	03/02
Vaxcyte Insider Sold Shares Worth $357,500, According to a Recent SEC Filing	02/02
Vaxcyte to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	01/02
Vaxcyte Insider Sold Shares Worth $1,980,900, According to a Recent SEC Filing	31/01
Vaxcyte Insider Sold Shares Worth $270,000, According to a Recent SEC Filing	31/01
Vaxcyte Prices $750 Million Public Offering at $64 Per Share	31/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Vaxcyte, Inc.

Acciones

PCVX

US92243G1085

Otros idiomas

Filtros